"Resverlogix has also decided to continue dosing until 250 events have occurred, which suggests that there could be ~270 events when the trial closes, improving the statistical powering in comparison with the original protocol. These historical numbers suggest that the trial can begin the adjudication process around the beginning of the year. While clinical events are independently assessed over an anticipated two month period, additional events will be added providing a topline readout in the first half 2019......We are in the final stretch for Resverlogix's Phase III BETonMACE trial and should achieve the target event rate around the turn of the year. To increase the power of the trial, Resverlogix will allow BETonMACE to run a couple months after 250 events occur."

I think this is the most recent analyst report. And it is just an analyst report......not official company statements. This Zack's report came out near year end. Based on the timeline statements above, analyst John Vandermosten seems to have believed what we we all led to believe at the AGM in Sept  2018 and Nov 6, 2018 BIO-Europe. At BIO-Europe, with 55 days left in 2018 Resverlogix re-iterated their previous guidance at the Sept 2018 AGM that end of dosing was expected by the end of 2018. We are now well past that. In fact, we are over double (112 days and counting) past that guidance. Feb 24, 2019 was 55 days past the turn of the year and 110 days since Nov 6, 2018 BIO-Europe. 

BearDownAZ